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Occidiofungin is a cyclic glyco-lipopeptide produced by Burkholderia contaminans. MICs against Candida species were between
0.5 and 2.0g/ml. Occidiofungin retains its in vitro potency in the presence of 5% and 50% human serum with a minimal lethal
concentration (MLC) of 2 and 4g/ml, respectively. Time-kill and postantifungal effect (PAFE) experiments of occidiofungin
against Candida albicanswere performed. The results demonstrate that occidiofungin is fungicidal. Occidiofungin was also
found to be a very stable molecule. It is resistant to extreme temperatures and pH andmaintains its activity following exposure
to gastric proteases.
Novel antifungals are needed because of the importance of fun-gal infections in organ transplant patients and the limitations
of currently available antifungal agents regarding their spectra of
activity and toxicities. Furthermore, there is a demand for new
antifungals, given the prevalence of azole-resistant fungal patho-
gens (1, 8). There are four major therapeutic groups of antifungal
agents: polyenes, azoles, allylamines, and echinocandins. The first
three groups primarily target ergosterol production or bind to
ergosterol, disrupting the fungal membrane (10, 18, 24). Ergos-
terol, much like cholesterol found in mammalian cells, is impor-
tant for maintaining proper cell permeability and fluidity. The
echinocandins, the fourth group, are synthetically modified lipo-
peptides that originate from the natural compounds produced by
fungi (15, 16). The antifungal activity of echinocandins is attrib-
uted to selective inhibition of 1,3--glucan synthesis by their
function as noncompetitive inhibitors of 1,3--glucan synthase
(5, 9, 14, 17, 27). There is a need to identify unique antifungals for
possible development of new therapeutics.
Occidiofungin is an antifungal peptide produced by the bacte-
rium Burkholderia contaminans MS14. This bacterial strain was
isolated from soil that suppressed brown patch disease of lawn
grass. A substantial amount of work has been done to characterize
the genetic locus and regulatory elements of the antifungal com-
pound (11–13). Structural characterization determined that oc-
cidiofungin is a cyclic glyco-lipopeptide (11, 25). Four structural
variants of the antifungal peptide, named occidiofungin A to D,
have been identified. They have masses of 1,200.39 Da, 1216.41
Da, 1234.17 Da, and 1250.41 Da, which correspond to the addi-
tion of oxygen and/or chlorine to the first compound. The target
and the mechanism of action of occidiofungin are still unknown.
The antifungal has been shown to inhibit a wide array of fungi
(25), such as Alternaria alternata, Aspergillus fumigatus, Aspergil-
lus niger, Fusarium oxysporum, Geotrichum candidum,Macropho-
mina phaseolina,Microsporum gypseum, Penicillium sp., Rhizocto-
nia solani MSCOT-1, and Trichophyton mentagrophytes. In
addition, two Pythium species were sensitive at nanomolar con-
centrations: Pythium spinosum and Pythium ultimum. Toxicolog-
ical evaluation of occidiofungin has been performed (W. Tan, et
al., submitted for publication). B6C3F1 mice were given a single
dose of occidiofungin up to 20 mg/kg of body weight or a daily
dose for 5 days at 2 mg/kg of body weight. Key effects were a
reduction in body and organ weights. Histological examination of
treatedmice did not exhibit any signs of organ-specific toxicity. In
this study, we tested the sensitivity of Candida species to occidio-
fungin with and without the presence of human serum. We also
performed simultaneous time-kill curves and postantifungal ef-
fect (PAFE) experiments on Candida albicans (ATCC 66027).
Lastly, we tested occidiofungin’s chemical stability against ex-
treme pH and temperature, as well as its stability against gastric
proteases.
MATERIALS AND METHODS
In vitro susceptibility testing. Occidiofungin was purified as previously
described (12). Microdilution broth susceptibility testing was performed
in duplicate according to the CLSIM27-A3method in RPMI 1640 growth
medium(buffered to a pH of 7.0 with morpholinepropanesulfonic acid
[MOPS]). Stock solutions (100) of occidiofungin were prepared in di-
methyl sulfoxide (DMSO). MIC endpoints for occidiofungin were deter-
mined by visual inspection andwere based on the wells that had no visible
growth (an optically clear well) after 24 h of incubation. Susceptibility
testing was done in duplicates. DMSO containing no antifungal agent was
used as a negative control.
Serum MICs. Susceptibility testing, as described above, was per-
formed in duplicate according to the CLSI M27-A3 method in RPMI
medium or YPD (yeast extract-peptone-dextrose) growth medium in the
presence of 5% and 50% (vol/vol) human serum (Sigma-Aldrich, St.
Louis, MO) (29). Given the turbidity of 50% serum, visual MIC determi-
nation was not possible. Therefore, 50l of cell suspension in each well of
the microtiter well was plated to determine the minimum lethal concen-
tration (MLC). MLC is defined in terms of a well that has no viable cells
(colonies) in the 50 l spread on a fresh agar plate. This is in accordance
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with the fungicidal activity being defined as a 99.9% reduction in the
number of CFU compared to the starting inoculum, which is approxi-
mately 1,000 CFU per ml (19).
Time-kill experiments and PAFE. Time-kill and PAFE experiments
provided important information about the activity of occidiofungin.
These studies determined whether occidiofungin is fungicidal or fungi-
static and its rate of activity. Fungicidal activity is defined as a 3-log re-
duction in cell count (20). The PAFE experiments determined the relative
effect occidiofungin has on cells exposed for a short time period. This
provides information about the affinity occidiofungin has to the cellular
target and whether the antifungal activity can be washed away following
exposure. Time-kill assays are essentially a measurement of CFU count
following the addition of the antifungal to the yeast. Time-kill and PAFE
experiments were done according to a method reported by Clancy et al.
(2). Candida albicans (ATCC 66027) colonies on 24-h-old YPD plates
were suspended in 9 ml of sterile water. The density was adjusted to a 0.5
McFarland standard (2, 6, 7, 19, 20) and was diluted 10-fold with RPMI
1640 medium to a final volume of 10 ml containing a final concentration
of 16, 4, 2, 1, and 0g/ml of occidiofungin. The cultures were incubated at
35°C with agitation. For the time-kill experiment, 100-l samples were
drawn, serially diluted, and plated on YPD medium for colony counts.
PAFE experiments were performed in a similar manner, except that fol-
lowing a 1-h exposure to the antifungal compound, the cells were pelleted
(1,400 g for 10min), washed three times and resuspendedwith 10ml of
prewarmed (35°C) RPMI 1640medium, and then returned to 35°C. Sim-
ilarly, 100-l samples at times 0, 2, 4, 8, 12, and 24 h were drawn and
plated for counting CFU. Each experiment was completed at least twice
for each sample.
Temperature stability. A temperature stability assay was performed
following a method similar to that reported by Wu et al. (30), except that
the procedure was optimized for determining the MIC using the CLSI
M27-A3 method. Occidiofungin was suspended in 0.5 ml of DMSO at a
concentration of 400g/ml. Subsequently, 60l (24g)was added to 540
l of 0.1M sodiumphosphate buffer (pH7.0) in a 1.8-ml Eppendorf tube.
Each tube was then placed in a water bath at 50, 60, 70, and 100°C for 30
min. Then, 200 l from each tube was added to the first well of each row
of a 48-well microtiter plate and serially diluted 2-fold in 100 l of RPMI
medium. Lastly, C. albicans (ATCC 66027) suspension was prepared us-
ing the CLSI protocol described above, and 900l was added to each well.
A negative control wasmade by combining 1ml ofDMSOwith 9ml of 0.1
M sodiumphosphate buffer and subsequently treated in the samemanner
as the occidiofungin samples. Themicrotiter plate was placed in the incu-
bator for 24 h at 35°C. The MIC was determined as described above.
pH stability. A pH stability assay was performed following a method
similar to that reported by Wu et al. (30), except that the procedure was
optimized for determining the MIC using the CLSI M27-A3 method.
Occidiofungin (160 g) was dried in eight separate 1.8-ml Eppendorf
tubes ranging from pH 2 to pH 9. The dried samples were resuspended in
1 ml of RPMI 1640 medium. Using stock solutions of 6 M HCl and 6 M
NaOH, the pHs of the samples were adjusted accordingly, and then sam-
ples were left at room temperature for 2 h. After a 2-h exposure, the pH
was readjusted to pH 7.0. The 160 g/ml solution was subsequently di-
luted 2-fold, resulting in concentrations of 160, 80, 40, 20, 10, 5, and 2.5
g/ml.Using a 48-wellmicrotiter plate, 100l of antifungal solution from
each of these tubeswas added to its correspondingwell. A suspension ofC.
albicans (ATCC 66027) following the CLSI methodology described above
was prepared, and 900 l of the suspension was added to each well con-
taining the antifungal solution. MICs were determined as described
above.
Protease stability. A protease stability assay was performed following
a method similar to that reported by Wu et al. (30), except that the pro-
cedure was optimized for determining the MIC using the CLSI M27-A3
method. Occidiofungin’s stability was tested against the digestive pro-
teases trypsin, chymotrypsin, and pepsin. For the trypsin assay, a 2 stock
solution of sodium phosphate buffer (0.134M, pH 7.6) and a 10 trypsin
stock solution (5.19 mg of trypsin in 1 ml of a 1 mM HCl solution) were
used. For the chymotrypsin assay, a 2 stock solution of Tris buffer con-
taining calcium chloride (200mMTris-HCl and 20mMcalcium chloride,
pH 8.0) and a 10 chymotrypsin stock solution (5.6 mg of chymotrypsin
in 1 ml of 1 mMHCl–2 mM calcium chloride) were used. For the pepsin
assay, a 2 stock solution of 20mMHCl and a 10 pepsin stock solution
(0.8 mg of pepsin in 1 ml of sterile deionized water) were used. The
reaction mixtures having a final volume of 250 l were prepared and
consisted of 25 l of 10 protease stock solution, 125 l of 2 stock
solution, 97.5l of sterile water, and 2.5l of DMSO. Then, 100l of the
reaction solution was added to two 1.8-ml Eppendorf tubes containing 8
g of occidiofungin and incubated at 35°C for 30min. A suspension ofC.
albicans (ATCC 66027) following the CLSI methodology described above
was prepared, and 900 l of the suspension was added to each tube con-
taining the antifungal solution and incubated for 4 h at 35°C. The number
of CFU was counted after 4 h of incubation by serial dilution and plating.
The plates were incubated at 35°C for 24 h, and CFU counts were deter-
mined. The assays were repeated for 60- and 120-min exposures to the
gastric proteases. Controls consisted of 10 stock solutions containing no
protease, no occidiofungin, and protease inhibitors for trypsin (phenyl-
methylsulfonyl fluoride [PMSF]), chymotrypsin, and pepsin (0.5 M
E-64 [Sigma], 0.1 M leupeptin, 0.7 M pepstatin A, 0.6 M bestatin,
37.5 M [4-(2-aminoethyl)benzenesulfonyl fluoride] AEBSF, 1 mM
PMSF, and 3 U of aprotinin [Trasylol]). Each experiment was completed
in duplicate.
Protease activity of trypsin, chymotrypsin, and pepsin was confirmed
using bovine serum albumin (BSA) as the substrate in place of occidio-
fungin in the reactionmixtures described above at a final concentration of
4.4 g/l. After 0, 30, 60, and 120 min at 35°C, 20-l aliquots were re-
moved, and the reaction was stopped by addition of 80 l of SDS loading
buffer. A volume equivalent to 4g of BSAwas electrophoresed on a 12%
SDS-PAGE gel, and proteins were visualized by Coomassie blue staining.
RESULTS
Susceptibility testing. The occidiofungin MIC for C. albicans, C.
glabrata, C. tropicalis, and C. parapsilosis was determined to be
within a range of 2.0 to 0.5 g/ml (Table 1). A caspofungin- and
fluconazole-resistant strain was tested. The MIC for the
caspofungin-resistant strain,C. albicans 11034,was 2g/ml, while
the MIC for the fluconazole-resistant strain, C. albicans 2677, was
1.0 g/ml. The most direct approach to determine the effect of
protein binding on the antifungal activity of occidiofungin is to
test the compound in the presence of serum. This provides infor-
TABLE 1 Occidiofungin MICs
Isolate
Occidiofungin MIC
(g/ml)
C. albicans TE 0.5
C. albicans LL 0.5
C. albicans 66027 1.0
C. albicans 24067 1.0
C. albicans 11034a 2.0
C. albicans 2677b 1.0
C. glabrata 66032 0.5
C. glabrata 200989 0.5
C. glabrata 2001 1.0
C. tropicalis 66029 1.0
C. tropicalis 13803 1.0
C. parapsilosis 90018 1.0
C. parapsilosis 34136 2.0
C. parapsilosis 90875 2.0
a Caspofungin-resistant strain (MIC 8 g/ml).
b Fluconazole-resistant strain (MIC 64 g/ml).
Ellis et al.
766 aac.asm.org Antimicrobial Agents and Chemotherapy
 o
n
 Septem
ber 11, 2018 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
mation as to the amount of unbound antifungal compound that is
present in blood. This information is also important for future
formulations for efficacy studies in an animalmodel. SerumMICs
were determined using 5% and 50% (vol/vol) human serum in
YPDmedium (Table 2) because C. albicans (ATCC 66027) and C.
glabrata (ATCC 66032) would not grow in the presence of 50%
serum inRPMI 1640medium. Therewas no difference in theMIC
values following the standard CLSI protocol against these two
strains using YPD medium and RPMI 1640 medium. Given the
turbidity of 50% serum, 50l of cell suspension from each well of
the microtiter plate was plated to determine the minimum lethal
concentration (MLC). Activity of occidiofungin was moderately
inhibited by 5% and 50% human serum. The MIC at 5% human
serumwas 1g/ml, while theMLCwas determined to be 2g/ml
forC. albicans (ATCC 66027) andC. glabrata (ATCC 66032). The
MLC at 50% human serum was 4 g/ml. Presumably, the 2- to
4-fold reduction in activity in the presence of serum is attributed
to protein binding. Amoderate decrease in activity in the presence
of serum is not uncommon for lipopeptides (3, 29).
Time-kill and PAFE experiments. The occidiofungin MICs
for the time-kill experiments were 2 g/ml at 24 h (Fig. 1A). The
higher MIC is most probably attributed to the 2- to 3-log increase
in cell density compared to the cell density in the CLSI protocol.
Time-kill experiments revealed that occidiofungin is fungicidal
(20). There was a log decrease in cell density after a 2-h exposure
with 1 MIC and 2 MIC and a 2-log decrease in cell density
following a 2-h exposure to occidiofungin with 8 MIC. There
was greater than a 3-log reduction by 8 h and 24 h with 8MIC
and 2 MIC, respectively. A 2-log decrease in cell density per-
sisted for 24 h with 1MIC dose. Interestingly, there appeared to
be only a moderate effect on the rate of growth at 0.5 MIC in
these experiments but no reduction from the starting inoculum.
This suggests that a threshold concentration is required for fungi-
cidal activity and that the fungal target needs to be saturated for
effect. The rapid drop in cell density after a 2-h exposure suggests
that the target for occidiofungin is critical for survival, while the
slow gradual decrease in cell density after a 2-h exposure may be
attributed to either the chance that these cells have not been satu-
rated with occidiofungin or possibly that they were in a different
cellular growth phase that is less susceptible to occidiofungin’s
effects.
In the PAFE experiments, the fungicidal activity of occidiofun-
gin at 2MIC was washed away (Fig. 1B). However, the effect of
exposure was still visible 3 h and 7 h after occidiofungin was re-
moved at 1MIC and 2MIC, respectively. Moreover, 8MIC
resulted in a greater than 3-log reduction in the cell count at 12 h.
The fungicidal effect of a 1-h exposure with 8MIC was perma-
nent and was delayed only by 4 h compared to the time-kill exper-
iments. Presumably, occidiofungin has a strong interaction with
the fungal cells, given that three washes were not enough to elim-
inate its fungicidal activity at 8MIC. Another possibility is that
occidiofungin may have an intracellular target. Irreversible cellu-
lar damage following a 1-h exposure is not probable, given that
viable cell counts were present 7 h after exposure in the PAFE
experiments.
Chemical stability experiments. Occidiofungin was exposed
to 50, 60, 70, and 100°C for 30 min. In this temperature stability
experiment, the MICs of occidiofungin against C. albicans 66027
were 1 g/ml for all temperatures. This suggests that occidiofun-
gin is stable following exposure to extreme temperatures. Occid-
iofunginwas incubated at pH2, 3, 4, 5, 6, 7, 8, and 9 for 2 h.No loss
in antifungal activity againstC. albicans 66027was observed in this
study. The MICs for all pH samples were 1 g/ml. Lastly, occid-
iofungin’s stability against the gastric proteases trypsin, chymo-
trypsin, and pepsin was evaluated (Fig. 2). Occidiofungin’s ability
to kill following exposure to each of these proteases for 30, 60, and
120 min was measured. The potency of occidiofungin did not
change following exposure to these proteases under the optimal
conditions for their proteolytic activity. Presumably, the cyclic
nature of occidiofungin provides protection against proteolytic
cleavage.
DISCUSSION
In vitro potency of occidiofungin against Candida species is in the
submicromolar range and is not drastically inhibited by the pres-
ence of serum. The reduction in activity in the presence of serum
is similar to the reduction observed for anidulafungin (29). In
addition, occidiofungin is fungicidal against C. albicans. The ini-
tial 1- to 2-log drop in cell density following exposure to occidio-
TABLE 2 Occidiofungin serum MICs and MLCsa
Isolate % Human serum MIC (g/ml) MLC (g/ml)
C. albicans 66027 5 1.0 2.0
C. albicans 66027 50 4.0
C. glabrata 66032 5 1.0 2.0
C. glabrata 66032 50 4.0
a Only the MLC is reported for 50% serum because of its turbidity.
FIG 1 Kill curves for time-kill (A) and postantifungal effect (B) experiments onCandida albicansATCC 66027. Symbols are as follows:□, 8MIC (16g/ml);
, 2MIC (4 g/ml); ‘, 1MIC (2 g/ml);, 0.5MIC (1 g/ml); and, control (0 g/ml).
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fungin is different from the results for caspofungin in the time-kill
and PAFE experiments (2). The differences in activities in the
time-kill and PAFE experiments suggest that occidiofungin has a
separate target from the lipopeptide caspofungin and, presum-
ably, from other echinocandins. These experiments support the
need for efficacy studies aimed at understanding occidiofungin’s
ability to treat systemic Candida infections.
Azoles are the only oral bioavailable drug for the treatment of
fungal infections. Lipophilic drugs generally have good colonic
absorption, but the oral bioavailability of caspofungin and anidu-
lafungin is10% (4, 22, 26). Low oral bioavailability of caspofun-
gin is attributed to drug permeability limitations to absorption
(22). However, in the same study caspofungin was reported to
have some instability at an acidic pH. A detailed analysis of the
chemical stability of echinocandins, caspofungin, anidulafungin,
or micafungin is not available. Occidiofungin is stable under ex-
treme temperature and pH. Furthermore, the compound is not
inactivated by the gastric proteases trypsin, chymotrypsin, and
pepsin. Given occidiofungin’s chemical stability, studies aimed at
understanding occidiofungin’s oral bioavailability are warranted.
Occidiofungin is a structurally unique antifungal peptide shar-
ing homology to cepacidine A (21, 23) and the recently discovered
burkholdines (28). Occidiofungin is the first antifungal from this
group to demonstrate its physical stability and in vitro activity
against a human fungal pathogen. These data suggest that further
studies on occidiofungin and presumably other antifungals within
this small group of antifungals are necessary. These compounds
may provide a new line of treatment for life-threatening fungal
infections.
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